ARCA biopharma, Inc. (ABIO)

NASDAQ: ABIO · IEX Real-Time Price · USD
3.350
+0.030 (0.90%)
At close: Jul 12, 2024, 4:00 PM
3.440
+0.090 (2.69%)
After-hours: Jul 12, 2024, 7:43 PM EDT
0.90%
Market Cap 48.60M
Revenue (ttm) n/a
Net Income (ttm) -6.00M
Shares Out 14.51M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,917
Open 3.280
Previous Close 3.320
Day's Range 3.280 - 3.400
52-Week Range 1.560 - 4.490
Beta 0.89
Analysts n/a
Price Target n/a
Earnings Date Jul 23, 2024

About ABIO

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Thomas A. Keuer
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ABIO
Full Company Profile

Financial Performance

Financial Statements

News

Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka

MILWAUKEE , June 4, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here to...

5 weeks ago - PRNewsWire

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma...

2 months ago - Business Wire

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: A...

2 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO

NEW YORK , April 9, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securiti...

3 months ago - PRNewsWire

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma...

3 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka

MILWAUKEE , April 3, 2024 /PRNewswire/ -- Ademi LLP is investigating ARCA (NASDAQ: ABIO) for possible breaches of fiduciary duty and other violations of law in its transaction with Oruka. Click here t...

3 months ago - PRNewsWire

Arca Biopharma stock ($ABIO) soars on merger news

Arca Biopharma Inc (NASDAQ: ABIO) more than doubled on Wednesday after announcing a merger agreement with Oruka Therapeutics. Oruka CEO comments on Arca Biopharma stock deal The combined company follo...

3 months ago - Invezz

ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of ARCA biopharma, Inc. (NASDAQ: ABIO) and Oruka Therapeutics is fair to ARCA shareholders...

3 months ago - Business Wire

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Merger to create a company focused on advancing Oruka's portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases

3 months ago - GlobeNewsWire

ARCA biopharma Announces 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIR...

5 months ago - GlobeNewsWire

ARCA biopharma Announces Third Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIR...

9 months ago - GlobeNewsWire

ARCA biopharma Announces Second Quarter 2023 Financial Results

WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapi...

1 year ago - GlobeNewsWire

ARCA biopharma Announces First Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic revi...

1 year ago - GlobeNewsWire

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic revi...

1 year ago - GlobeNewsWire

James Flynn Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors.

1 year ago - GlobeNewsWire

ARCA biopharma Announces Third Quarter 2022 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic revi...

1 year ago - GlobeNewsWire

ARCA biopharma Announces Second Quarter 2022 Financial Results

WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapi...

2 years ago - GlobeNewsWire

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.

2 years ago - GlobeNewsWire

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor.

2 years ago - GlobeNewsWire

ARCA biopharma Announces First Quarter 2022 Financial Results

WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

2 years ago - GlobeNewsWire

ARCA biopharma Establishes Special Committee of the Board of Directors

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap...

2 years ago - GlobeNewsWire

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized w...

2 years ago - Benzinga

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highl...

2 years ago - GlobeNewsWire

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022 Topline data from Phase 2b ASPEN-COVID-19 cl...

2 years ago - GlobeNewsWire

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapi...

2 years ago - GlobeNewsWire